A Phase 2 interventional study of Obeldesivir and Obeldesivir Placebo in RSV Infection, sponsored by Gilead Sciences. Terminated at 56 sites in 2 countries. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Respiratory Syncytial Virus Infections with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · United States.
Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, this one is the 118th largest by enrollment of the 122 interventional ones that give a count, is one of 8 that started in 2025, is one of 28 in phase 2, and was the 136th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →10 of the 145 studies in Respiratory Syncytial Virus Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Australia
Ages 18–80 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Shionogi · Sites in United States, Argentina, Bulgaria and 5 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, South Africa and 1 more country
Ages 0+ · Healthy volunteers
Clover Biopharmaceuticals USA, LLC · Sites in United States
Ages 60–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: Up to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 40 · Phase 3 29 · Phase 4 3
First in 1997; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 88 across the 122 interventional studies, 300 across the 23 observational. Of the 127 that completed or were terminated, 61 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
106 of 145 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 8 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
5 of the studies in Respiratory Syncytial Virus Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026749Phase 3University of Alabama at BirminghamAzithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children | 2027-07-01 |
| NCT07214571ShionogiA Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease | 2026-12-30 |
| NCT07092865GlaxoSmithKlineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant | 2027-01-12 |
| NCT06686654Sanofi Pasteur, a Sanofi CompanyStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | 2027-01-18 |
| NCT06817889Fred Hutchinson Cancer CenterRemdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to check if obeldesivir (ODV; GS-5245) is safe and well-tolerated by children with respiratory syncytial virus (RSV) infection. It will also look at how well ODV helps reduce the time it takes for children to feel better and for their RSV symptoms to improve.
The primary objectives of this study are: a) to evaluate the safety and tolerability of ODV in pediatric participants with RSV infection; b) To evaluate the efficacy of ODV on time to alleviation of targeted RSV symptoms in pediatric participants with RSV infection.
Pediatric participants will be enrolled as follows:
Key Inclusion Criteria:
Participants assigned male or female at birth, from birth to \< 5 years of age who meet one of the following criteria, where permitted according to local law and approved nationally and by relevant institutional review board or independent ethics committee:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing ≥ 12 kg to \< 20 kg, will receive ODV 175 mg, orally, twice on Day 1, followed by ODV 116.6 mg, orally, twice daily on Days 2 to 5.
Drug: Obeldesivir
Participants weighing ≥ 6 kg to \< 12 kg, will receive ODV 116.6 mg, orally, twice on Day 1, followed by ODV 58.3 mg, orally, twice daily on Days 2 to 5.
Drug: Obeldesivir
Participants weighing ≥ 6 kg to \< 12 kg, will receive placebo-to-match ODV, orally, twice daily on Days 1 to 5.
Drug: Obeldesivir Placebo
Administered orally
Also known as: ODV, GS-5245
Administered orally
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28
TEAEs were defined as any adverse events that began on or after the date of first dose of study drug up to the date of last dose of study drug up to Day 28. The percentage of participants who experienced at least one TEAE was assessed from Day 1 through Day 28.
Time frame: Up to Day 28
Percentage of Participants Who Experienced Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities by Day 28
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose up to Day 28. A treatment-emergent laboratory abnormality severity was graded according to the Division of AIDS (DAIDS) Version 2.1. Grade 0: Values that do not meet the criteria for an abnormality of at least Grade 1;Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Potentially life-threatening. The percentage of participants who experienced Grade 3 or 4 laboratory abnormalities was assessed from Day 1 through Day 28.
Time frame: Up to Day 28
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms by Day 28
Alleviation of targeted RSV symptoms was defined as achievement of 2 consecutive daily assessments with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1, or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).
Time frame: Up to Day 28
PK Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir
AUCtau is defined as area under the plasma concentration-time curve during a dosing interval (AUCtau) of GS-441524, the active metabolite of obeldesivir.
Time frame: Day 5 (predose, 2.5, and 3.5 hours post-dose)
PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir
Cmax is defined as maximum plasma concentration of GS-441524, the active metabolite of obeldesivir.
Time frame: Day 1 (0.25, 0.75, and 2 hours post-dose); Day 5 (predose, 2.5, and 3.5 hours post-dose)
PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir
Ctrough is defined as the trough observed drug concentration \[measured concentration at predose of Day 5 (taken directly before next administration)\].
Time frame: Day 5: Predose
Change From Baseline in RSV Nasal Swab Viral Load at Day 5
Nasal swab samples was used to assess RSV viral load by reversetranscriptase-quantitative polymerase chain reaction (RT-qPCR), respiratory coinfection by multiplex respiratory pathogen PCR, potential infectious viral titer assessment, and potential resistance testing (by sequencing and/or phenotyping). Baseline was defined as the last available value collected on or prior to first dose of study drug.
Time frame: Baseline, Day 5
Time to Sustained Alleviation of Targeted RSV Symptoms by Day 28
Sustained alleviation of targeted RSV symptoms was defined as 3 daily consecutive assessments (48-hour period) with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1; or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to sustained alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).
Time frame: Up to Day 28
Time to Resolution of Targeted RSV Symptoms by Day 28
Resolution of targeted RSV symptoms was defined as: for 2 daily consecutive assessments, improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score \>2; no increase or an improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score of 2; no increase in score for any targeted RSV symptom with baseline score of 1. The time to resolution of targeted RSV symptoms by Day 28 was calculated as the resolution date/time minus the first dose date/time. Targeted RSV symptoms referred to RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).
Time frame: Up to Day 28
Number of Participants With Palatability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5
Caregivers were asked to rate how the study drug tasted to their child. A questionnaire was administered to caregivers to assess palatability. Palatability was assessed by caregivers using a questionnaire on Day 1 and Day 5 with response options: Super Good, Good, Maybe Good or Maybe Bad, Bad, or Super Bad.
Time frame: Days 1 and 5
Number of Participants With Acceptability Questionnaire Response as Assessed by the Caregiver at Days 1 and 5
Caregivers were asked to evaluate how easy it was for children to take the study drug. A questionnaire was administered to caregivers to assess acceptability. Acceptability was assessed by caregivers using a questionnaire with response options: Super Easy, Easy, Maybe Easy or Maybe Hard, Hard, or Super Hard. The questionnaire evaluated how easy it was for children to take the study drug.
Time frame: Days 1 and 5
Participants were enrolled at study sites in the United States.
| Milestone | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Started | 1 | 2 | 1 |
| Completed | 1 | 1 | 1 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 |
TEAEs were defined as any adverse events that began on or after the date of first dose of study drug up to the date of last dose of study drug up to Day 28. The percentage of participants who experienced at least one TEAE was assessed from Day 1 through Day 28.
| percentage of participants | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28 | 0 | 100.0 | 100.0 |
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose up to Day 28. A treatment-emergent laboratory abnormality severity was graded according to the Division of AIDS (DAIDS) Version 2.1. Grade 0: Values that do not meet the criteria for an abnormality of at least Grade 1;Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Potentially life-threatening. The percentage of participants who experienced Grade 3 or 4 laboratory abnormalities was assessed from Day 1 through Day 28.
| percentage of participants | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Percentage of Participants Who Experienced Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities by Day 28 | 0 | 0 | 100.0 |
Alleviation of targeted RSV symptoms was defined as achievement of 2 consecutive daily assessments with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1, or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).
| days | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms by Day 28 | 5.4 (5.4 to 5.4) | NA (NA to NA) | — |
AUCtau is defined as area under the plasma concentration-time curve during a dosing interval (AUCtau) of GS-441524, the active metabolite of obeldesivir.
| nanograms times hours per mL(ng*h/mL) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV |
|---|---|---|
| PK Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir | NA ± NA | NA ± NA |
Cmax is defined as maximum plasma concentration of GS-441524, the active metabolite of obeldesivir.
| ng/mL | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV |
|---|---|---|
| PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir | NA ± NA | NA ± NA |
Ctrough is defined as the trough observed drug concentration \[measured concentration at predose of Day 5 (taken directly before next administration)\].
| ng/mL | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV |
|---|---|---|
| PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir | 960 ± NA | 159 ± NA |
Nasal swab samples was used to assess RSV viral load by reversetranscriptase-quantitative polymerase chain reaction (RT-qPCR), respiratory coinfection by multiplex respiratory pathogen PCR, potential infectious viral titer assessment, and potential resistance testing (by sequencing and/or phenotyping). Baseline was defined as the last available value collected on or prior to first dose of study drug.
| log10 copies/mL | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Baseline | 4.89 | 8.45 | — |
| Change from Baseline at Day 5 | -2.79 | -2.12 | — |
Sustained alleviation of targeted RSV symptoms was defined as 3 daily consecutive assessments (48-hour period) with improvement in score by at least 1 point for any targeted RSV symptom with baseline score is \> 1; or no increase in score for any targeted RSV symptom with baseline score of 1, assessed from Day 1 to Day 28. The time to sustained alleviation of targeted RSV symptoms by Day 28 was calculated as the symptom alleviation date minus the first dose date. Targeted RSV symptoms referred to the RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).
| days | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Time to Sustained Alleviation of Targeted RSV Symptoms by Day 28 | 5.4 (5.4 to 5.4) | NA (NA to NA) | — |
Resolution of targeted RSV symptoms was defined as: for 2 daily consecutive assessments, improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score \>2; no increase or an improvement in score resulting in score of ≤2 for any targeted RSV symptom with baseline score of 2; no increase in score for any targeted RSV symptom with baseline score of 1. The time to resolution of targeted RSV symptoms by Day 28 was calculated as the resolution date/time minus the first dose date/time. Targeted RSV symptoms referred to RSV symptoms (cough, respiratory signs, RSV signs, behavior impact).
| days | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Time to Resolution of Targeted RSV Symptoms by Day 28 | 3.4 (3.4 to 3.4) | NA (NA to NA) | — |
Caregivers were asked to rate how the study drug tasted to their child. A questionnaire was administered to caregivers to assess palatability. Palatability was assessed by caregivers using a questionnaire on Day 1 and Day 5 with response options: Super Good, Good, Maybe Good or Maybe Bad, Bad, or Super Bad.
| Participants | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Day 1 - Super Bad | — | 1 | 0 |
| Day 1 - Bad | — | 0 | 0 |
| Day 1 - Maybe Good or Maybe Bad | — | 0 | 0 |
| Day 1 - Good | — | 0 | 1 |
| Day 1 - Super Good | — | 0 | 0 |
| Day 5 - Super Bad | — | 0 | 0 |
| Day 5 - Bad | — | 1 | 0 |
| Day 5 - Maybe Good or Maybe Bad | — | 0 | 0 |
| Day 5 - Good | — | 0 | 1 |
| Day 5 - Super Good | — | 0 | 0 |
Caregivers were asked to evaluate how easy it was for children to take the study drug. A questionnaire was administered to caregivers to assess acceptability. Acceptability was assessed by caregivers using a questionnaire with response options: Super Easy, Easy, Maybe Easy or Maybe Hard, Hard, or Super Hard. The questionnaire evaluated how easy it was for children to take the study drug.
| Participants | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Day 1 - Super Hard | 0 | 0 | 0 |
| Day 1 - Hard | 0 | 1 | 0 |
| Day 1 - Maybe Easy or Maybe Hard | 0 | 0 | 0 |
| Day 1 - Easy | 0 | 0 | 1 |
| Day 1 - Super Easy | 1 | 1 | 0 |
| Day 5 - Super Hard | 0 | 0 | 0 |
| Day 5 - Hard | 0 | 1 | 0 |
| Day 5 - Maybe Easy or Maybe Hard | 0 | 0 | 1 |
| Day 5 - Easy | 1 | 0 | 0 |
| Day 5 - Super Easy | 0 | 0 | 0 |
Collected over All-cause Mortality and Adverse Events: Up to 5 days plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Cohort 1: Part A (Group 3) - ODV | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Cohort 1: Part A (Group 3) - Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| TachypnoeaRespiratory, thoracic and mediastinal disorders | 0/1 | 1/2 | 0/1 |
| Event | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo |
|---|---|---|---|
| Respiratory syncytial virus infectionInfections and infestations | 0/1 | 1/2 | 1/1 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/1 | 0/2 | 1/1 |
| ConstipationGastrointestinal disorders | 0/1 | 1/2 | 0/1 |
| BronchiolitisInfections and infestations | 0/1 | 1/2 | 0/1 |
| Metapneumovirus infectionInfections and infestations | 0/1 | 1/2 | 0/1 |
The Safety Analysis Set included all study participants who were randomized into the study and had received at least 1 dose of study drug.
| Age, Continuous(months) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo | Total |
|---|---|---|---|---|
| Mean | 48 ± NA | 7 ± 0.7 | 6 ± NA | 17 ± 20.8 |
| Age, Customized(Participants) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo | Total |
|---|---|---|---|---|
| < 2 years | 0 | 2 | 1 | 3 |
| ≥ 2 to < 5 years | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 1 | 4 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 1 | 1 | 1 | 3 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Part A (Group 2) - Obeldesivir (ODV) | Cohort 1: Part A (Group 3) - ODV | Cohort 1: Part A (Group 3) - Placebo | Total |
|---|---|---|---|---|
| United States | 1 | 2 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2025 to primary completion in Apr 2025, 1 month.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obeldesivir
Respiratory Syncytial Virus Infections →